Teaching NeuroImages:

Positive apraclonidine test in Horner syndrome

Robert K. Shin, MD
Andrew G. Cheek, MD

Address correspondence and
reprint requests to Dr. Robert K.
Shin, Department of Neurology,
110 South Paca Street, Third
Floor, Baltimore, MD 21201
rshin@som.umaryland.edu

Figure Apraclonidine reverses anisocoria in Horner syndrome

(A) Right ptosis and miosis of the right pupil are present. (B) After instillation of apraclonidine, the right ptosis resolves, and the right pupil dilates, resulting in reversal of anisocoria and confirming the diagnosis of Horner syndrome.

A 36-year-old woman reported right eyelid drooping immediately after anterior cervical discectomy and fusion. Examination 2 weeks later revealed right miosis and right ptosis (figure, A). Instillation of one drop of 0.5% apraclonidine in both eyes resulted in reversal of anisocoria and resolution of ptosis (figure, B).

Apraclonidine, a selective α_2 agonist used to reduce intraocular pressure, has only weak α_1 action and, therefore, has little to no effect on a normal pupil. Patients with Horner syndrome may develop denervation hypersensitivity of α_1 receptors on the iris dilator muscle, resulting in mydriasis of the affected pupil in response to apraclonidine. Reversal of ptosis may also occur. This denervation

hypersensitivity may develop as soon as 36 hours after injury.¹

Apraclonidine is a US Food and Drug Administration–approved medication, routinely used in glaucoma treatment, and is a readily available alternative to cocaine in the diagnosis of Horner syndrome.²

REFERENCES

1. Lebas M, Seror J, Debroucker T. Positive apraclonidine test 36 hours after acute onset of Horner syndrome in dorsolateral pontomedullary stroke. *J Neuroophthalmol* 2010;30:12–17.
2. Freedman KA, Brown SM. Topical apraclonidine in the diagnosis of suspected Horner syndrome. *J Neuroophthalmol* 2005;25:83–85.

From the Departments of Neurology (R.K.S.) and Ophthalmology and Visual Sciences (R.K.S., A.G.C.), University of Maryland School of Medicine, Baltimore.

Disclosure: Dr. Shin has received speaker honoraria from Bayer Schering Pharma and Teva Pharmaceutical Industries Ltd. Dr. Cheek reports no disclosures.

Neurology®

Teaching *NeuroImages*: Positive apraclonidine test in Horner syndrome

Robert K. Shin and Andrew G. Cheek

Neurology 2011;76:e100

DOI 10.1212/WNL.0b013e31821a4454

This information is current as of May 16, 2011

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/76/20/e100.full
References	This article cites 2 articles, 0 of which you can access for free at: http://n.neurology.org/content/76/20/e100.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Neuro-ophthalmology http://n.neurology.org/cgi/collection/all_neuroophthalmology Clinical neurology examination http://n.neurology.org/cgi/collection/clinical_neurology_examination Eyelids http://n.neurology.org/cgi/collection/eyelids Pupils http://n.neurology.org/cgi/collection/pupils
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2011 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.